Background and Aims: More than half of patients with Crohn's disease [CD] develop disease complications requiring aggressive medical therapy or surgery over time. However, predicting disease course and treatment response remains difficult. We therefore identified distinctive serum analytes associated with disease activity and course in newly diagnosed, untreated patients at presentation and during their follow-up. Methods: In a pilot study, a multiplex immunoassay analysis on 36 markers was performed on serum from 20 CD patients at the time of primary diagnosis following endoscopic evaluation. The 12 most potent markers associated with disease activity, phenotype and course were analysed in a consecutive cohort of 66 CD patients at diagnosis and follow-up [n = 39]. A healthy control group [n = 20] was included as a reference. Results: CD patients had higher baseline levels of sTNF-R2 [p = 0.001], sIL-2R [p = 0.0001], and MMP-1 [p = 0.001] compared with healthy controls. Serial measurements revealed that these three analytes dropped statistically significantly from baseline level during remission and were high during exacerbation. Great decline of sTNF-R1 levels was found during remission, with 6.7-fold lower levels than in healthy controls [p = 0.015]. Patients who did not respond to initial prednisone treatment had higher baseline levels of sTNF-R2 [p = 0.001]. Patients experiencing relapses during follow-up had lower baseline sTNF-R2 and VCAM levels compared with patients with long-lasting remission.
Introduction
Crohn's disease [CD] is an idiopathic chronic inflammatory disease, primarily affecting the gastrointestinal tract and belonging to the group of inflammatory bowel diseases [IBD] . CD is characterised by lifelong episodes of relapsing-remitting disease, and covers a wide spectrum of disease phenotypes. Disease behaviour at diagnosis consists of uncomplicated mucosal inflammation in 70-80% of patients, whereas 20-30% have already developed complications with stricturing or penetrating disease. 1, 2 At presentation of the disease, younger age [< 40] , perianal or stricturing disease, involvement of the upper gastrointestinal tract, penetrating disease, and smoking are clinical determinants associated with a complicated disease course. 3, 4 Approximately 50% of CD patients are expected to develop disease complications over time, requiring aggressive medical therapy such as biologics, immunomodulators or surgery. Disease monitoring, on which clinical decisions depend, include clinical scores [often inaccurate 5 ], radiological techniques, endoscopy [including histological analysis], and faecal calprotectin. Despite clinical determinants and disease monitoring, it is difficult to predict disease course and response to therapy in clinical practice. Therefore, treatment is based on generic principles, without much focus on the individual patient. Reliable predicting indicators [biomarkers] on disease course and response to therapy would help in focusing on fast and accurate therapy in the individual patient and prevent administration of potentially toxic and expensive medication to nonresponsive patients. 6 Some efforts in this respect have been made in a study that identified CD8 + T cell transcriptional signatures associated with frequently relapsing disease in IBD and in a study on serological antibodies in IBD. 7, 8 The involvement of a disrupted immune system in initiation and progression of CD has been established, but the driving immune regulatory factors involved in the early stages of CD are still poorly understood. It has been suggested that CD originates as a result of a dysregulated immune response to gut bacteria, characterised by the infiltration of inflammatory cells derived from the circulation into the gut mucosa of a genetically susceptible host. 9 In a previous study, we focused on the characterisation of the lymphocytic infiltrate in colonic biopsies and identified a subpopulation of naïve T-cells that was associated with the clinical phenotype at presentation. 10 In addition, the local production of cytokines upon stimulation of the mucosal biopsies was related to the infiltrated T cell subpopulations and the clinical presentation. This local release of cytokines and the expression of adhesion molecules and cytokine receptors are thought to contribute to recruitment of the inflammatory cells and perpetuation of local inflammation. 11 The localised immunological process in the gut most likely has systemic reflections, as CD is known to be a systemic disease with extra-intestinal manifestations. Therefore, the primary aim of this study was to identify distinctive serum analytes associated with disease activity in newly diagnosed, untreated CD patients at presentation and during follow-up. Our secondary aim was to study the correlation of these serum analytes with disease phenotype and course.
Materials and Methods

Patient selection and sample collection
An initial analysis was performed in a pilot cohort of 20 newly diagnosed, adult CD patients. We selected this cohort based on clinical and mucosal immunological phenotype as presented earlier. 10 Subsequent analysis was performed in a consecutive cohort of CD patients [n = 66] and an age-and sex-matched healthy control group [n = 20]. Patients were recruited before initial diagnostic ileocolonoscopy, at the outpatient clinic of the Department of Gastroenterology and Hepatology at Rijnstate Hospital, Arnhem, The Netherlands. After clinical, endoscopic, histopathological and, when indicated, radiographic evaluation, all patients met the accepted international diagnostic criteria of CD. 12 Disease phenotype [location and behaviour] was assessed according to the Montreal classification, at primary diagnosis and at latest follow-up. 13 The Harvey-Bradshaw Index [HBI] was used to score clinical symptoms. The simple endoscopy score for CD [SES-CD] was used to assess endoscopic disease severity.
14 Mild endoscopic disease activity was defined as a score of 4-10, moderate activity as [11] [12] [13] [14] [15] [16] [17] [18] [19] , and severe activity as ≥ 20.
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In general, therapeutic management of CD after diagnosis was done according to the step-up approach. 16 Accelerated use of antitumour necrosis factor [TNF] therapy was occasionally initiated in case of complex perianal disease, in addition to surgical treatment. In accordance with the step-up approach, systemic steroids were started as induction therapy. This was usually followed by the initiation of maintenance treatment [mainly thiopurines]. In case of steroiddependent, -refractory, or -intolerant disease, anti-TNF therapy was initiated, usually in combination with thiopurines or methotrexate. If disease did not respond to conventional treatment, surgery was considered. In case of relapse, escalation of maintenance treatment was considered. Remission was defined as: disappearance of clinical symptoms after induction treatment [HBI < 5] ; general physician's assessment in combination with endoscopic remission [SES-CD < 4]; and/or normalization of imaging and/or decreasing parameters of inflammation like C-reactive protein [CRP] and/or faecal calprotectin. Relapse was defined as occurrence of new symptoms [HBI > 4] after achieving clinical remission, combined with either increased faecal calprotectin levels and/or abnormalities on imaging and/or endoscopic activity [SES-CD > 3], resulting in escalation of maintenance treatment or surgical intervention. Disease course included any of the following parameters: initial steroid response; long-lasting remission [no relapses during follow-up]; progression to stricturing, penetrating, or perianal disease; initiation of anti-TNF during follow-up; or surgery during follow-up. Venous blood samples were drawn following endoscopic evaluation at primary diagnosis, before any immunomodulating treatment was initiated. Serum samples were coded and stored at −20°C until analysis. Follow-up blood samples were collected in 39 patients, either in remission or during an exacerbation.
Multiplex immunoassay
A total of 36 cytokines, chemokines, growth factors, soluble receptors, and other mediators [hereafter denoted by 'analytes'] were selected [see Figure 1 ], based on their relevance in CD and other [auto]inflammatory diseases. [17] [18] [19] [20] [21] The following panel of analytes was tested in the pilot cohort: IL-1RA, IL-1α, IL-1β, IL-6, IL-10, IL-12p70, IL-13, IL-17, IL-18, IL-21, IL-23p19, IL-33, IL-37, TNF-α, IFN-γ, CCL-2/MCP-1, CCL-3/MIP-1α, CCL-4/MIP-1β, CCL-5/ RANTES, CCL-19/MIP-3β, CXCL-8/IL-8, CXCL-10/IP-10, CXCL-13/BLC, GM-CSF, EGF, VEGF, sICAM, sVCAM, sTNF-R1, sTNF-R2, sIL-2R/sCD25, sIL-6R/sCD126, MMP-1, MMP-3, MMP-9, S100A8/MRP8. Candidate analytes that showed to be associated with clinical phenotype at diagnosis, endoscopic disease severity at diagnosis, and disease course [ Table 1; and Supplementary Tables 1  and 2 
Statistical analysis
The Shapiro-Wilk test was used to test the normality of variables. As most variables were skewed, log transformation was applied. Non-parametric tests were used for all log-transformed variables. Continuous variables were described as median and interquartile range [IQR] and compared with Mann-Whitney tests. Categorical variables were described as absolute frequencies and compared with Kruskal-Wallis analysis followed by Dunn test. Due to the exploratory nature of the pilot group, no adjustments were made to p-values for multiple comparisons. In the consecutive cohort, we report p-values corrected for multiple testing using the Holm-Bonferroni correction. We adjusted for age and gender when testing for association between analyses and disease phenotype as they are common confounders (although no association with age and gender was found in our study). We also adjusted for SES-CD and symptom duration when an association was found between them and an analyte. Analyte values measured in blood samples at baseline and those collected during follow-up were compared using Wilcoxon matchedpairs signed-rank test. We computed receiver operating characteristic 
Ethical considerations
Written informed consent was obtained from each participating patient before any study-related procedure was performed. The procedures were performed in accordance with the Declaration of Helsinki. The regional medical ethics committee approved the study protocol.
Results
Serum analytes in a pilot cohort of newly diagnosed, untreated, CD patients
The complete panel of 36 analytes [ Figure 1 ] was tested in a pilot cohort of 20 newly diagnosed CD patients [ Table 1 and Supplementary Tables 1 and 2] : IL-37, CCL-5/RANTES, CCL-19/MIP-3β, CXCL-13/BLC, sVCAM, sTNF-R1, sTNF-R2, sIL-2R/sCD25, sIL-6R/sCD126, MMP-1, MMP-9, and S100A8/MRP8, and followed up in a consecutive cohort of CD patients [n = 66] and age-and sex-matched healthy controls [n = 20].
Association of analyte levels with disease phenotype at diagnosis
Baseline characteristics of the consecutive cohort are shown in Table 2 . All MMP-9 levels were above standard range and were not included for further analyses. Compared with healthy controls, CD patients had higher baseline levels of sTNF-R2 [fold change p1. Figure 2a ]. However, after correction for age and gender, SES-CD severity and symptom duration were not independent factors associated with MMP-1 levels. SIL-2R was higher in severe endoscopic disease compared with both mild [p = 0.009] and moderate disease [p = 0.041, Figure 2b ]. After correction for age, gender, and symptom duration, this remained a significant independent factor [p = 0.009]. STNF-R2 serum concentrations were higher in patients with severe endoscopic disease activity compared with patients with mild disease activity [p = 0.038, corrected for age and gender, Figure 2c ].
Association of analyte levels with disease course
Patients who did not respond to prednisone at initial treatment [n = 9, 24%] had 1. 
Differential analyte expression in CD patients in remission and with active disease
The same 11 analytes were measured during the follow-up of 39 CD patients of the consecutive cohort [see Table 2 for patient characteristics]. Patients in remission at follow-up blood collection [n = 29] had a median follow-up duration of 35 months [IQR 13-55], which was not significantly different from patients with an exacerbation (n = 10, median follow-up of 32 months , p = 0.58).
Compared with baseline, many analyte levels dropped during remission [see Table 3 and During remission there was no significant difference from the levels of healthy controls, except for sTNF-R1 which was 6.7-fold lower in remission patients than in controls [p = 0.015, Table 3 ].
In patients with an exacerbation at the time of follow-up blood collection, there was an overall decrease of analyte levels compared with baseline [ Table 3 and Figure 3 ], but this was only statistically significant for sTNF-R1 [p = 0.007]. In the patients with an exacerbation, the following followed-up analyte levels were higher than in healthy controls: sIL-2R . We were unable to determine the effect of treatment modality on analyte levels during follow-up, due to fragmentation of patient groups.
Determination of optimal analyte thresholds
Based on these results, we aimed to determine the optimal thresholds of baseline and follow-up analytes to discriminate different groups of patients. For each analyte, we constructed ROC curves and used Youden´s index to define the optimal threshold.
To discriminate CD and controls, baseline sTNF-R2 showed a good sensitivity [91%] but a relatively low specificity [60%], whereas sIL-2R and MMP-1 had good specificity [95%] but relatively low sensitivity [59% and 50%, respectively] [Supplementary CD, Crohn's disease; FU, follow-up; IQR, interquartile range; HBI, Harvey-Bradshaw Index; SES-CD, Simple Endoscopic Score for Crohn's disease; GI, gastrointestinal tract; 5-ASA, 5-aminosalicylic acid. a p < 0.05 between CD pilot cohort and consecutive CD cohort; no statistically significant differences for any of the other characteristics between these groups. b No statistically significant differences for any characteristics between follow-up and baseline cohorts. Table 4 ].
Baseline sTNF-R2 was the best analyte to discriminate initial steroid non-responders from responders, with an optimal threshold at 2371.58 pg/ml corresponding to an AUC of 0.845, a sensitivity of 89%, and a specificity of 86% [ Figure 4 , and Supplementary Table 5 , available as Supplementary data at ECCO-JCC online].
Baseline VCAM and sTNF-R2 had good sensitivity and acceptable specificity to discriminate between CD patients with future relapsing disease and CD patients with long-lasting remission. The most accurate single marker was sTNF-R2 with an AUC of 0.693; and when combining both analytes, the AUC increased to 0.738, corresponding to a sensitivity of 50%, a specificity of 97%, and both positive and negative predictive values higher than 70% [ Supplementary Figure 2 and Supplementary Follow-up analytes sIL-2R, CCL-19, CXCL-13, and sTNF-R1 were all able to discriminate between CD patients with a current exacerbation and patients in remission, with sensitivity and specificity above 70% [ Figure 5 and Table 4 ]. The combination of these markers gave a very good discrimination between the two groups, with an AUC of 0.914 and corresponding sensitivity of 80%, a specificity of 93%, and positive and negative predictive values of 80% and 93%, respectively.
Discussion
In the present study, several cytokines, chemokines, soluble receptors, growth factors, and other mediators were analysed in the sera of newly diagnosed, untreated CD patients. At time of primary diagnosis, these patients had significant higher levels of sTNF-R2, sIL-2R, and MMP-1 compared with healthy controls. Higher sIL-2R was an independent factor associated with ileocolonic disease over ileal disease. Furthermore, sTNF-R2 and sIL-2R were independently associated with endoscopic disease severity. Serial measurements revealed that sTNF-R1, sTNF-R2, sIL-2R, and MMP-1 were candidate markers of disease activity, as they all dropped significant from baseline levels during remission and were high during exacerbation. Initial non-response on prednisone therapy was associated with higher baseline levels of sTNF-R2. Furthermore, higher baseline values of sTNF-R2 and VCAM were associated with an indolent disease course without relapses, whereas lower levels were associated with relapsing disease. Remarkably, almost all pro-inflammatory cytokines, except for IL-6 and IL-18, were undetectable at baseline in most of the CD patients in the pilot cohort. 17 Particularly striking is the fact that TNF-α is undetectable in serum from 16 out of 20 patients. Reported series on serum TNF-α are conflicting, differing from raised levels 22 to normal 23 or undetectable. 24 As raised TNF-α concentrations have been found in the inflamed mucosa of IBD patients, 25 an undetectable serum TNF-α concentration suggests a sequestration of pro-inflammatory cytokines from the systemic circulation towards the inflamed gut mucosa, or increased binding to soluble TNF receptors [sTNFRs] . This may put forward an explanation of the ineffectiveness of etanercept─an engineered human sTNF-R2, preferentially neutralising soluble TNF-α 26 ─as opposed to the beneficial therapeutic effects of infliximab and adalimumab, which bind both soluble and membrane-bound TNF-α. 27 In the consecutive cohort of patients, baseline levels could not predict the development of severe disease complications like perianal disease or stricturing and penetrating disease. However, we still cannot rule out the value of baseline serum analytes in predicting occurrence of complications in CD, since longer follow-up duration [over 10 years] is needed to conclude on this topic. Furthermore, in accordance with the numbers in our study, it is known that 20-30% of patients have already developed complications at time of diagnosis.
1,2 We did find an association of lower baseline serum levels of sTNF-R2 and VCAM with relapsing disease behaviour, whereas higher levels raised the probability of more quiescent disease after primary treatment. The combination of both markers demonstrated the best predictive value [AUC 0.738]. VCAM is expressed by activated endothelium and regulates lymphocyte, monocyte, eosinophil, and basophil adhesion, promoting their recruitment into the inflamed mucosa. In line with our results, positive serum VCAM levels were previously shown to be predictive of sustained clinical remission after infliximab cessation. 28 The authors hypothesized that this soluble adhesion molecule may prevent adherence of inflammatory cells to the vascular endothelium by competition, thereby diminishing gut inflammation.
Our serial analyte measurement in patients [a group in remission and a group during exacerbation at blood collection] ensured an analysis of the evolution of these different analytes during the course of disease. The fact that most serum analyte levels [10/11] dropped in CD patients in remission, is an important observation as this implies direct association of these serological markers with mucosal disease activity in CD. Our results therefore demonstrate that the value of serum analytes in CD patients should be analysed and interpreted in combination with disease activity. Further research with a different design needs to be initiated, to study the effect of different treatment modalities on serum analytes in larger [sub]groups.
Remarkably, whereas most followed-up levels in remission were comparable to those from healthy controls, the followed-up level of sTNF-R1 was almost 7-fold lower in patients in remission compared with healthy controls. In patients with an exacerbation at follow-up, sTNF-R1 levels also dropped compared with their baseline levels; however, they were five times higher than in patients during remission and comparable to healthy controls. This finding on sTNF-R1 gives an insight into the initial immune response in CD patients. The evolution over time hints at a possible role for serial measurement of sTNF-R1 to monitor disease activity. STNFRs are able to neutralise TNF, preventing its interaction with membrane-bound receptors and therefore functioning as physiological attenuators. 29 Membrane-bound TNF-R1 is ubiquitously expressed and binds soluble and transmembrane TNF-α, and its function is primarily pathogenic, inducing inflammation, tissue degeneration, and apoptosis. 30 On the other hand, membrane-bound TNF-R2 preferentially binds transmembrane TNF-α and its function is primarily homeostatic, inducing tissue regeneration, cell proliferation, and cell survival.
Administration of TNF to humans was shown to induce higher sTNF-R1 and sTNF-R2, probably by a shedding mechanism. 31, 32 In our study, higher levels of sTNF-R2, but not sTNF-R1, were found in serum of CD patients compared with controls at baseline. As shedding of sTNF-R2 belongs to the armoury of regulatory T lymphocytes to inhibit TNF-α mediated inflammation, these higher baseline levels and their decline during disease remission might portray the body's attempt to inhibit the TNF-α proinflammatory downstream effects. [33] [34] [35] The fact that higher sTNF-R2 baseline values were associated with prednisone non-response and early stepup treatment, could represent another disease mechanism in these patients. Elevated baseline sTNF-R2 might be associated with high mucosal TNF levels and a defective TNF-TNFR2 binding at the site of active inflammation, leading to increased shedding of sTNF-R2 in the circulation.
This group of patients might benefit more from anti-TNF treatment early in the course of disease, than might patients with low baseline sTNF-R2 levels. In two other studies in treated CD patients with a disease duration over 9 years, elevated sTNFRs were found in patients with clinically active disease. 24, 36 One study found increased sTNFR levels in all CD patients, both during remission and active disease, 36 whereas the other study described significantly lower levels of both sTNFRs in patients in remission. They also showed that sTNF-R2 levels decreased after infliximab therapy, whereas it did not affect sTNF-R1. 24 In rheumatoid arthritis and sarcoidosis patients, similar results were obtained where higher baseline levels of sTNF-R2 correlated with [prolonged] therapeutic response to anti-TNF treatment. 34, 37 In the present study, sTNF-R2 showed an accuracy of AUC = 0.845 in predicting steroid response in early CD patients. It would be interesting to further investigate whether sTNF-R2 could act as a marker in determining which CD patients will benefit most from steroids or anti-TNF treatment.
Next to the sTNFRs, sIL-2R and MMP-1 also emerged as potential markers of disease activity. Both were elevated at baseline compared with healthy controls and decreased in patients in remission at follow-up, and higher levels were found at follow-up in patients during exacerbation compared with healthy controls. Furthermore, sIL-2R was also independently associated with ileocolonic disease and a severe endoscopic score. The membrane-bound receptor for interleukin-2 is expressed among many leukocytes such as activated T cells and regulatory T cells, natural killer cells, activated B cells, monocytes, and eosinophils. 38 Proteolytic cleavage seems to be responsible for the production of circulating sIL-2R. In line with our results, sIL-2R levels were previously found to be elevated in CD patients [under treatment] compared with controls, and levels correlated with disease activity and treatment response. [39] [40] [41] [42] [43] Despite its potential as biomarker, demonstrated in several studies, sIL-2R has not yet reached clinical practice. In sarcoidosis, sIL-2R has been proposed as marker of disease activity. 44 Increased levels have also been observed in diseases like rheumatoid arthritis and systemic lupus erythematosus. 45, 46 Therefore, sIL-2R cannot be used as diagnostic tool but might be interesting as a marker of disease activity in CD.
Matrix metalloproteinases [MMPs] are enzymes with an important role in tissue remodelling, as they are capable of degrading extracellular matrix proteins. MMP-1 breaks down interstitial collagens and has been suggested to have an anti-fibrotic role, as its overexpression attenuated liver and cardiac fibrosis in animal models. 47, 48 Previously, MMP-1 plasma concentrations were found to be elevated in patients with active ulcerative colitis compared with controls. 49, 50 However, to our knowledge, MMP-1 serum levels have not been evaluated in CD patients. MMP-1 expression was reported to be increased in biopsy specimens of inflamed colonic mucosa of IBD patients and showed a good correlation with the histological degree of inflammation. 51, 52 In accordance with ulcerative colitis, we find higher baseline levels of MMP-1 in active CD compared with controls. We extended on this finding with its decrease in serial measurements in patients during remission, whereas levels during exacerbation were higher than in healthy controls. Therefore, we believe MMP-1 might be a useful marker of disease activity; MMP-9 seems to be an important marker in CD. 53 Unfortunately, as MMP-9 levels in our study were all extrapolated above standard range [both in patients and in healthy controls], these values were not reliable for further analysis. However, we do believe that it would be worthwhile to further investigate this marker using higher dilutions.
CCL-19, CXCL-13, sTNF-R1, and sIL-2R could differentiate between remission and exacerbation at follow-up blood collection. CCL-19 was the most accurate single marker [AUC = 0.833], but the best accuracy was reached by a combination of these four analytes [AUC = 0.914]. Further research is needed to elucidate if the combination of these markers can be used to identify patients with a disease exacerbation, without the need for endoscopy or faecal calprotectin examination. Chemokines CXCL-13 and CCL-19 are known to be required for the development and maintenance of secondary and tertiary lymphoid organs, as well as the entry of lymphocytes and dendritic cells into these lymphoid organs. 54, 55 Circulating levels possibly reflect the expression in the inflamed gut. Serum and mucosal CXCL-13 was found to be elevated in IBD patients compared with controls. [56] [57] [58] The differentiating potential of elevated serum levels of CCL-19 and CXCL-13 between exacerbation and remission might be explained by the formation and resolution [respectively] of tertiary lymphoid organs in the inflamed gut. 59 Previous studies on mediators of inflammation in CD patients have assessed individual analytes or combined a limited set of analytes in serum or intestinal mucosa. In these studies, heterogeneous patient cohorts with divergent disease durations and IBD phenotypes were included, and almost invariably patients were receiving immunomodulatory treatment. A recent literature overview identified 89 research papers on cytokines and chemokines in IBD patients, with a median sample size of 31 CD patients mainly receiving pharmacological therapy. 18 Results of these studies are therefore inconclusive, as analyte levels are associated with disease activity and potentially also with treatment modality. Our serial results showed that patients in remission and patients in relapse displayed different evolution of serum analyte profiles and therefore these results should be analysed and interpreted separately.
We identified several limitations and possible explanations for the difference in results between the pilot cohort and the consecutive cohort. Due to the exploratory nature of the pilot group, no adjustment for multiple comparisons were made to p-values. Furthermore, as the sample size was small we could not perform multivariate analysis. Due to the disease heterogeneity in CD, we were limited by relatively small groups of different disease phenotypes. The follow-up duration of patients was probably too short to determine the true value of these baseline analyte levels in predicting future disease course with respect to the development of complications.
The strength of our study is that we analysed a full spectrum of analytes in two well-characterised cohorts of CD patients at the time of diagnosis, all with endoscopically confirmed inflammation. Our baseline results are not biased by the influence of therapy, as all patients were untreated. Compared with other papers on this topic, we had access to a relatively large group of CD patients and performed repeated measurements during follow-up. Our analysis was based on released proteins, and not on mRNA levels which can be hampered by regulatory events that may inhibit the translation of mRNA to protein. Here, we extended on the proposed immunological basis for CD heterogeneity, with several candidate serum analytes that might reflect the underlying complex immune processes in CD and seem to be logical and promising candidates as non-invasive biomarkers to predict disease activity and course.
Conclusion
There is a very small window of opportunity for the analysis of early inflammatory processes in CD patients, as therapy that influences the immune system is usually initiated soon after diagnosis. The repeated measurements in patients at diagnosis and during followup identified sTNF-R1, sTNF-R2, sIL-2R, and MMP-1 as potential markers of disease activity. Furthermore, sTNF-R2 and VCAM were associated with prednisone response and disease course. These candidate markers are easily accessible and implementable in daily practice and therefore warrant further investigation.
